Marc Vandelaer appointed as interim Chief Executive Officer (CEO) of IBBL


Mr Vandelaer has been appointed as interim CEO of IBBL, while Dr Larue takes over the general management of LIH (Luxembourg Institute of Health) starting from 1 January 2016. Dr Larue will succeed Dr Jean-Claude Schmit as CEO (by interim), who has been managing the LIH for the last 8 years, and was recently appointed Director of Health at the Luxembourg Ministry of Health.

Marc Vandelaer has a combined experience in life science and healthcare, in addition to 15+ years in IT and management in those domains. He holds a M.Sc. in cellular and molecular biology from the University of Liège in Belgium.

He began his career as a research scientist and a scientific coordinator at the University Hospital Centre of Liège (Belgium). In the early 2000s, he co-founded a company specialized in e-commerce services for global 2000+ corporations in Luxembourg (with subsidiaries in U.S. and in India). Thereafter, he joined Siemens Belgium where he supervised the implementation of Laboratory Information Management Systems (LIMS) and Process Analytical Technologies (PAT) in a large set of multinational industrial and life science companies.

Before joining IBBL in 2014, Marc Vandelaer was IT Director at Eurofins Scientific Group responsible for onshore and offshore teams dedicated to support a Pharma and AgroSciences study management program.

“It is with great pleasure that I accept to temporarily take over the wheel for 2016,” declares Mr Vandelaer. “With the help of a great team behind me, I look forward to leading IBBL on its course to becoming an international centre of excellence in biobanking.”